10-K: Antiaging Quantum Living Inc. 10-K Filing Analysis

Antiaging Quantum Living Inc. files its annual 10-K report, detailing a strategic shift towards proprietary health products and therapy services, alongside financial performance and operational updates.

Summary

• Antiaging Quantum Living Inc. (AAQL) has filed its annual report for the fiscal year ended March 31, 2026.
• The company has undergone a significant strategic pivot, transitioning from online advertising and technical platform services to focus exclusively on the supply and distribution of proprietary brand health products and therapy services.
• This strategic shift, which began in June 2025 and concluded in January 2026, involved ceasing online platform technical operation support and maintenance services.
• Revenues increased by 26.47% to $1,034,385 in FY2026 from $817,898 in FY2025, driven by new therapy services and health/beauty product sales.
• Gross profit significantly improved to $702,123 (67.9% margin) in FY2026 from $428,517 (52.4% margin) in FY2025 due to higher margins on new offerings.
• Operating expenses increased by 26.18% to $1,537,524 in FY2026 from $1,218,476 in FY2025, primarily due to increased rental and facility costs.
• The company reported a net loss of $837,646 in FY2026, an increase from $720,409 in FY2025, largely due to higher operating expenses.
• As of March 31, 2026, the company has an accumulated deficit of $2,247,358 and a working capital deficit of $459,038.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the increased net loss, growing operating expenses, and the auditor's substantial doubt about the company's going concern status, despite revenue growth and improved gross margins.

Positives

• Revenue increased by 26.47% to $1,034,385 in FY2026.
• Gross profit increased by 63.85% to $702,123 in FY2026.
• Gross margin improved significantly from 52.4% in FY2025 to 67.9% in FY2026, driven by higher-margin new business lines.
• The company successfully transitioned its business model to focus on proprietary health products and therapy services, aiming for enhanced brand value and supply chain control.
• Cash and cash equivalents increased to $503,486 as of March 31, 2026, from $370,549 as of March 31, 2025.

Negatives

• The company reported a net loss of $837,646 for the year ended March 31, 2026, an increase of 16.27% from the prior year's net loss of $720,409.
• Operating expenses increased by 26.18% to $1,537,524 in FY2026, primarily due to higher rental and facility costs.
• The company has an accumulated deficit of $2,247,358 as of March 31, 2026.
• A working capital deficit of $459,038 was reported as of March 31, 2026.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern due to recurring losses, operating losses, and accumulated deficit.

Risks

• The company is economically dependent on limited customers and suppliers, and the loss of relationships with them could have a material adverse effect on its financial condition, results of operations, and cash flows.
• The strategic shift to proprietary products and services, while intended to enhance brand value, materially impacts near-term consolidated financial results and comparability with historical statements.
• The company's auditor has identified substantial doubt about its ability to continue as a going concern.
• The company has identified material weaknesses in its internal controls over financial reporting, specifically a lack of US GAAP knowledge and segregation of duties.

Future Outlook

The company is strategically shifting its focus to proprietary health products and therapy services, aiming to enhance brand value and establish long-term control over its supply chain. This transition is expected to impact near-term financial results and comparability with historical statements. Management plans to improve profitability and cash flow generation to meet operating needs.

Management Comments

• We view this transition as a vital strategic pivot to enhance our brand value and establish long-term control over our product supply chain.
• Consequently, while our consolidated revenues will materially decrease in the near term due to the loss of the technical service revenue, our general and administrative (G&A) expenses and overall operating cost structure will not experience a proportional decrease.
• Managements plan to alleviate the substantial doubt about the Companys ability to continue as a going concern include attempting to improve its business profitability, its ability to generate sufficient cash flow from its operations and execute the business plan of the Company in order to meet its operating needs on a timely basis.
• Management does not believe that any of these material weaknesses [in internal controls] materially affected the results and accuracy of its financial statements.

Industry Context

StockSavvy.ai notes that Antiaging Quantum Living Inc.'s strategic pivot aligns with a broader trend in the health and wellness sector towards direct-to-consumer proprietary brands and specialized services, aiming for greater margin control and brand differentiation in a competitive market.

Comparison to Industry Standards

• The company's gross margin of 67.9% in FY2026 is strong, particularly for a company transitioning into health products and services, suggesting potential for higher profitability compared to many online advertising or technical service providers.
• However, the significant operating loss of $835,401 and accumulated deficit of $2,247,358 indicate challenges in scaling operations and achieving profitability, which is a common hurdle for emerging companies in the health and wellness space.
• The auditor's 'going concern' warning is a critical flag, suggesting that the company's financial stability is precarious, a situation not uncommon for small businesses undergoing significant strategic shifts but requiring close investor scrutiny.

Corporate Governance

Legal Proceedings

• To the best of the Company's knowledge and based on information available as of March 31, 2026, the Company is not involved in any material claims or legal actions arising from the ordinary course of business.

Related Party Transactions

• Advances from Mr. Barry Wan (CEO, CFO, etc.) for working capital purposes totaled $980,000 as of March 31, 2026, and $520,000 as of March 31, 2025. These advances are unsecured, non-interest-bearing, and due on demand.
• Promissory notes issued to Mr. Barry Wan ($428,789.50) and New Lite Ventures LLC ($29,571.00, controlled by Mr. Wan) in December 2024 were subsequently assigned and converted into Class A Common Stock on November 25, 2025.
• The company's President provides office space at no cost.

Stakeholder Impact

• Shareholders: The company's financial performance, including net losses and accumulated deficit, along with the auditor's going concern warning, may negatively impact shareholder value and confidence.
• Creditors/Lenders: The company's working capital deficit and going concern issues could raise concerns for existing and potential lenders.
• Employees: The company's financial instability could create uncertainty regarding job security and future compensation.
• Suppliers: Dependence on a single supplier for key goods presents a risk to the supply chain, potentially impacting product availability for customers.

Next Steps

• Continue to improve business profitability and generate sufficient cash flow from operations.
• Execute the business plan to meet operating needs on a timely basis.
• Implement expense control measures to support liquidity.
• The company plans to continue improving its online platform to expand its customer base.
• The company will search for different business opportunities to be acquired.

Key Dates

Recommendation

While the company has shown revenue growth and improved gross margins due to a strategic shift, the increased net loss, significant operating expenses, working capital deficit, and the auditor's going concern warning present substantial risks. The company's future hinges on its ability to successfully execute its new business model and manage its expenses. Therefore, a 'hold' recommendation is appropriate, pending further evidence of sustained profitability and operational stability.

Keywords

Antiaging Quantum Living Inc., 10-K Filing, Annual Report, Health Products, Therapy Services, Business Transformation, Financial Results, Going Concern